KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Notes Payables (2016 - 2025)

AbbVie has reported Notes Payables over the past 14 years, most recently at $2.5 billion for Q4 2025.

  • Quarterly Notes Payables changed N/A to $2.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $2.5 billion for FY2025, N/A changed from the prior year.
  • Notes Payables was $2.5 billion for Q4 2025 at AbbVie, down from $3.8 billion in the prior quarter.
  • Over five years, Notes Payables peaked at $3.8 billion in Q3 2025 and troughed at $1.0 million in Q4 2022.
  • The 5-year median for Notes Payables is $14.0 million (2021), against an average of $665.6 million.
  • Year-over-year, Notes Payables tumbled 92.86% in 2022 and then surged 53000.0% in 2025.
  • A 5-year view of Notes Payables shows it stood at $14.0 million in 2021, then tumbled by 92.86% to $1.0 million in 2022, then skyrocketed by 100.0% to $2.0 million in 2023, then soared by 50.0% to $3.0 million in 2024, then skyrocketed by 83200.0% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Notes Payables are $2.5 billion (Q4 2025), $3.8 billion (Q3 2025), and $2.0 billion (Q2 2025).